Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Publisher： Karger

E-ISSN： 1662-6575|8|3|461-465

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.8, Iss.3, 2015-10, pp. : 461-465

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001

By  

Case Reports in Oncology, Vol. 9, Iss. 1, 2016-03 ,pp. : 164-170

Karger

Access to resources Recommend Favorite

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

By  

Case Reports in Oncology, Vol. 9, Iss. 2, 2016-05 ,pp. : 285-289

Karger

Access to resources Recommend Favorite

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-03 ,pp. : 276-280

Karger

Access to resources Recommend Favorite

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-01 ,pp. : 79-85

Karger

Access to resources Recommend Favorite

Diffuse Idiopathic Neuroendocrine Cell Hyperplasia Causing Severe Airway Obstruction in a Patient with a Carcinoid Tumor

By  

Respiration, Vol. 73, Iss. 5, 2006-09 ,pp. : 690-693

Karger

Access to resources Recommend Favorite